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Structural variation and single-nucleotide variation of the comple-
ment factor H (CFH) gene family underlie several complex genetic
diseases, including age-related macular degeneration (AMD) and
atypical hemolytic uremic syndrome (AHUS). To understand its di-
versity and evolution, we performed high-quality sequencing of
this ∼360-kbp locus in six primate lineages, including multiple hu-
man haplotypes. Comparative sequence analyses reveal two dis-
tinct periods of gene duplication leading to the emergence of four
CFH-related (CFHR) gene paralogs (CFHR2 and CFHR4 ∼25–35 Mya
and CFHR1 and CFHR3 ∼7–13 Mya). Remarkably, all evolutionary
breakpoints share a common ∼4.8-kbp segment corresponding to
an ancestral CFHR gene promoter that has expanded indepen-
dently throughout primate evolution. This segment is recurrently
reused and juxtaposed with a donor duplication containing exons
8 and 9 from ancestral CFH, creating four CFHR fusion genes that
include lineage-specific members of the gene family. Combined
analysis of >5,000 AMD cases and controls identifies a significant
burden of a rare missense mutation that clusters at the N terminus
of CFH [P = 5.81 × 10−8, odds ratio (OR) = 9.8 (3.67-Infinity)]. A
bipolar clustering pattern of rare nonsynonymous mutations in
patients with AMD (P < 10−3) and AHUS (P = 0.0079) maps to
functional domains that show evidence of positive selection dur-
ing primate evolution. Our structural variation analysis in >2,400
individuals reveals five recurrent rearrangement breakpoints that
show variable frequency among AMD cases and controls. These
data suggest a dynamic and recurrent pattern of mutation critical
to the emergence of new CFHR genes but also in the predisposition
to complex human genetic disease phenotypes.
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The complement factor H (CFH) gene family cluster onchromosome 1q31.3 has long been recognized for its bio-
medical relevance to human disease. Candidate gene studies (1,
2), as well as the application of high-density single-nucleotide
polymorphism microarrays (3–6) and massively (exome and
targeted) parallel sequencing technologies (7, 8), have identified
both common and rare mutations associated with susceptibility
to complex disease [age-related macular degeneration (AMD),
systemic lupus erythematosus (SLE), and atypical hemolytic
uremic syndrome (AHUS)]. In particular, this locus is recognized
as one of two major genetic contributors to risk of AMD (9–12),
the leading cause of vision loss in the developed world.
Factor H is an abundant serum glycoprotein produced pri-
marily in the liver, which is essential for regulating the alternative
pathway of the complement system (13). Here, factor H acts at
the level of C3 (14), resulting in down-regulation of alternative
pathway-mediated complement activation and complement ho-
meostasis. The N terminus displays complement regulatory ac-
tivity by acting as a cofactor for factor I-mediated cleavage of
C3b and facilitating the decay of C3 convertase (decay-
accelerating activity) (15, 16). The C terminus of the protein
mediates cell surface binding and target recognition with ligands
C3b, C3d, and heparin (17, 18), and represents a critical domain
for discrimination between self- and non–self-surfaces.
At the genomic sequence level, the CFH gene family com-
prises six genes spanning almost 360 kilobase pairs (kbp). The
five CFH-related gene paralogs (CFHR3, CFHR1, CFHR4,
CFHR2, and CFHR5) extend telomerically adjacent to the an-
cestral CFH gene, which includes four genes (CFHR1–CFHR4)
embedded within a series of segmental duplications (SDs)
arranged in tandem across the locus. The presence of these SD
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blocks renders this region genetically unstable and prone to un-
equal crossing over and gene conversion. Large population-based
studies have identified several rare and common structural variants
mediated by the SD architecture (19, 20). A common ∼84-kbp
deletion that completely removes two CFH paralogs (CFHR3
and CFHR1) has been identified as one of the most population-
stratified copy number variants (CNVs) in the human genome
(20), with African (AFR) populations particularly enriched for
the deletion allele (>50%) (21).
The common CFHR3/1 deletion haplotype associates with
several complex genetic diseases, albeit with differential risk.
The specific deletion, for example, is associated with protection
in AMD but with risk for SLE and AHUS (6, 22, 23). In addition,
there are reports of de novo rearrangements and rare disease-
associated CNVs that show alternate breakpoint signatures and
evidence of CFHR fusion proteins (24–26), most of which are
associated with nonallelic homologous recombination (NAHR)
and interlocus gene conversion (IGC) events between SD blocks
(27). Moreover, the evolutionary juxtaposition of incomplete SD
blocks has driven the emergence of novel CFH-like gene paral-
ogs with overlapping, but diverse, functions distinct from their
ancestral progenitors (28, 29). Incomplete SD of the CFH pro-
genitor locus was likely critical to the neofunctionalization and
subfunctionalization of CFHR genes (30).
Duplicated regions of the genome, such as the CFH gene
family, are frequent sites of misassembly within reference ge-
nomes (31, 32) due to the difficulties in resolving closely related
paralogous genes. In addition, studies of genetic diversity are
often incomplete due to the complexity of structural variation
and the limitations of having a single reference genome. For
example, an examination of the most complete primate genome
assemblies for this locus shows more than 93 gaps in the se-
quence assembly, with most corresponding to regions of recent
SD. The goals of this project were to (i) reconstruct the complex
evolutionary history of this locus by generating high-quality se-
quences from nonhuman primate (NHP) lineages (chimpanzee,
gorilla, orangutan, macaque, and marmoset) and (ii) understand
the complete sequence structure of this locus from a set of six
diverse human haplotypes, including protective and at-risk dis-
ease haplotypes, as well as differences in their transcriptional
potential. We develop specialized resources [large-insert bacte-
rial artificial chromosome (BAC)/fosmid libraries] and apply
long-read single-molecule real-time (SMRT) sequencing. We
then use these data to investigate >2,400 AMD cases and con-
trols to discover disease-associated protein-coding mutations,
characterize structural variation breakpoints, and determine the
IGC frequency within patients. Our results reveal a pattern of
nonrandom and recurrent mutation where structural variation,
disease susceptibility, and positive selection are linked.
Results
Copy Number Diversity. We initially assessed copy number varia-
tion at the CFH 1q31.3 locus by assessing read depth from ge-
nome sequence data mapped back to the human reference
genome from 2,367 human [224 from Human Genome Diversity
Project (HGDP) (33) and 2,143 from 1000 Genomes Project
(1KG) (19)] and 86 NHP (34) genomes. Among humans, we
readily distinguish two large copy number polymorphisms that
are ∼84 kbp and ∼120 kbp in length and include three paralo-
gous CFH-related genes (CFHR3, CFHR1, and CFHR4) (Fig. 1
A and B and SI Appendix, Fig. S1). The 84-kbp CFHR3/CFHR1
deletion is highly differentiated (maximum Vst = 0.28) between
AFR and East Asian (EAS) populations and shows the highest
allele frequency among AFR and South Asian populations
(0.36 and 0.47, respectively) (Fig. 1C and Datasets S1 and S2). In
particular, >57% of Yoruban and 41% of Gujarati individuals
contain at least one copy of the deletion allele. The ∼120-kbp
deletion of CFHR1 and CFHR4 is rarer but twofold more fre-
quent among AFR and EAS populations than Europeans (Fig.
1C and Dataset S1). By contrast, the apparent reciprocal dupli-
cations of these deletion events occur at low frequency across all
human populations.
Analysis among NHP species (chimpanzee, bonobo, gorilla,
and orangutan) reveals distinct lineage-specific patterns of copy
number variation. The sampled orangutan genomes show little
copy number variation at 1q31.3, indicating a fairly static genome
organization where many of the large-scale duplications oc-
curred in the common ancestor of humans-gorillas-chimpanzees
and bonobos (Fig. 1D). Among NHPs, we identified several re-
gions of copy number expansion, including an ∼15-kbp region
containing the 3′ exons of CFHR4 and an ∼28-kbp region con-
taining the last three exons of CFH that had expanded to high
copy among chimpanzees and bonobos (e.g., some bonobos
carried between six and 10 copies of this duplicated segment).
The most unstable region among NHPs maps to a 30-kbp seg-
ment (SD-E) that appears to have been subject to independent
and recurrent expansions in both chimpanzees and gorillas (Fig.
1D). This sequence element also mediates the recurrent rear-
rangement associated with the CFHR1/CFHR3 deletion in hu-
mans, which is protective against AMD.
Sequence Assembly of Human Haplotypes and Breakpoint Analyses.
To gain insight into the structural diversity of the 1q31.3 CFHR
locus, we sequenced and assembled 99 large-insert clones (BACs
and fosmids) from 12 diverse human genome libraries using
SMRT sequencing (SI Appendix, SI Materials and Methods and
Datasets S3 and S4). We generated and deposited >7.2 Mbp of
high-quality finished sequence, producing data from six alterna-
tive reference haplotypes, four of which contain alternate structural
configurations (Fig. 2 and Dataset S5). To avoid confusion with
previously defined single-nucleotide variant haplotypes (H1–H5) (1),
we designate these alternative haplotype structures as S1–S4 (Fig. 2).
The haplotypes range in size from 294 kbp (S3) to 540 kbp (S4), and
their length varies almost exclusively due to unequal crossover be-
tween tandem SDs. We designate the human reference genome
(GRCh37 and GRCh38) as S1 and identify two genomes [NA19129
(Yoruban) and CHM1 (hydatidiform mole)] with organizations con-
sistent to the reference. S1 carries all five CFHR paralogs (CFHR1–
CFHR5) and a series of SDs, the largest of which, SD-D (∼42 kbp)
and SD-E (∼30 kbp), correspond to the breakpoints associated with
common deletion CNVs (Dataset S6).
Using these high-quality sequences, we refine the breakpoint
intervals associated with each structural haplotype, taking ad-
vantage of paralogous sequence variants (PSVs) (20) that dis-
tinguish SDs mediating the rearrangements (SI Appendix, SI
Materials and Methods). Based on the S2 structural haplotype
(SI Appendix, Figs. S2 and S3A) obtained from AFR samples
NA18517 and NA19449, we initially define a region of 6.4 kbp
within the duplication SD-E as the location of the breakpoints
associated with the common AMD-protective 84.68-kbp CFHR1–
CFHR3 deletion. HMMSeg (35) further refines the breakpoint to a
489-bp sequence interval mapping to a dense cluster of long in-
terspersed nuclear element (LINE)/L1 repeat elements embedded
within SD-E (SI Appendix, Fig. S4 and Dataset S7). It is interesting
that this predicted breakpoint is flanked by several kilobases
of perfect sequence identity [including the breakpoints defined
previously (22)]. Sequence analysis shows that the proposed
breakpoints map to an ∼15-kbp IGC hotspot between the SD-E
paralogs, complicating precise localization of the breakpoints
(SI Appendix, Fig. S5 and Dataset S8).
Similarly, using the S3 sequence assembly, we refine the
CFHR1/CFHR4 (121,898 bp) deletion breakpoints to a 59-bp
sequence interval completely contained within a LINE/L2 repeat
element inside the SD-D duplication (SI Appendix, Fig. S3B and
Dataset S7). Interestingly, sequence analysis of the supposed
reciprocal duplication (S4) of the CFHR1–CFHR4 deletion
event predicts that breakpoints differ. The S4 haplotype creates
a 124-kbp tandem duplication block of 99.7% sequence identity.
A multiple sequence alignment and HMMSeg refine the break-
point to a 1,179-bp region corresponding to a cluster of LINEs
and short interspersed nuclear elements (SINEs) (SI Appendix,



























Fig. S3C and Dataset S7). This repeat cluster maps 4.3 kbp
downstream of the breakpoint associated with the AMD-protective
CFHR1/CFHR4 deletion haplotype, and therefore does not rep-
resent the reciprocal product of an unequal crossover event.
Evolution of CFHR Duplications. To build a model for the evolution
of this locus, we sequenced and assembled 20 additional large-
insert BAC clones from three NHP species (chimpanzee, gorilla,
and orangutan) and representatives of the Old World (macaque)
and NewWorld (marmoset) monkey lineages (Fig. 3 and Dataset
S3). To estimate the evolutionary age of the duplications, we
construct a series of phylogenetic trees for each SD and estimate
the divergence of the corresponding haplotypes (SI Appendix,
Fig. S6). A comparison of these assembled sequences (∼1.92
Mbp) with current NHP genome assemblies showed that all
existing reference sequences were incomplete and/or misassembled
(SI Appendix, Figs. S7 and S8). In total, we resolve 93 euchromatic
gaps, adding 218.4 kbp of sequence to these reference assemblies.
This included missing and lineage-specific CFHR genes, SDs, and
common repeat annotations (Datasets S9–S11). Over the last 40 My
of primate evolution, we estimate that this locus has expanded
about threefold almost entirely as a result of SD (Fig. 3). Based on
the human CFH gene structure, we note that all SD events were
incomplete but harbored protein-encoding exons with respect to the
ancestral gene model. All duplications occurred in close proximity
to their ancestral source (<100 kbp) (Fig. 3 and Dataset S6).
We predict at least seven evolutionary structural changes
(ranging from 1.6 to 40.2 kbp in size) to reconcile the organi-
zation of the CFHR locus between modern humans and other
primates (Fig. 3). Using the common S1 haplotype as a point of
reference for human genome organization, we observe that
CFHR4 and CFHR2 arose after divergence of the Old World and
New World monkey lineages (∼35 Mya) as a result of in-
dependent duplications of CFH. In the case of CFHR4, exons 7,
8, and 9 formed a cassette that was subsequently tandemized,
underwent exon exaptation, and became juxtaposed to a pro-
moter element mapping to a 4.8-kbp segment (SD-B). The origin
of the SD-B promoter element is complicated as no homology
can be identified within the progenitor CFH locus, but we do
identify it in association with other CFHR expansions in different
mammalian lineages. For example, the mouse contains four
copies of the promoter element associated with two rodent-
specific CFHR paralogs. We also note that SD-B is present
twice in the macaque in association with CFHR4 and a derived
CFHR homolog, CFH-L3, which appears specific to Old World
monkey lineages, and it is also part of a gorilla-specific duplication
that could not be sequence-resolved at the level of clone-based
assembly (SI Appendix, Fig. S9).
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Fig. 1. CFHR copy number diversity in humans and great apes. (A) Schematic of the organization of the CFHR family (208 kbp) with respect to common copy
number (CN) polymorphisms. Deletions (gray) and duplications (blue) are shown in the context of a heat map for nine human genomes [CN estimated based
on mapping sequence reads to singly unique nucleotide k-mers (SUNKs)]. Gene models are shown in the context of SD orientation (colored arrows). (B) Scatter
plots depicting CN estimates obtained using whole-genome sequencing data from 224 diverse humans from the HGDP. CN is estimated by sequence read
depth using SUNK identifiers over CFHR3 and CFHR1 and CFHR1 and CFHR4. Frequency and Vst analyses are described in Datasets S1 and S2. (C) Pie charts per
population group estimate the deletion/duplication allele frequency for CFHR3/CFHR1 and CFHR1/CFHR4 CNVs. AFR and South Asian (SAS) populations show
enrichment of the CFHR3/CFHR1 deletion allele (0.35 and 0.47) relative to East Asian (EA/EAS) and European (EUR) populations (0.04 and 0.19). The rarer
CFHR1/CFHR4 deletion is twice as frequent in AFR and EA/EAS (0.027 and 0.035) populations compared with EUR and SAS populations (0.008 and 0.01).
(D) Diploid aggregate CN heat maps over CFHR SDs from 86 NHP genomes. Regions of CN expansion include the 3′ regions of CFHR4 and CFH. The chimpanzee
and bonobo genomes demonstrate increased CN (six to 10 copies) for an ∼28-kbp segment containing the last three exons of the ancestral CFH. This segment
is subject to independent and recurrent expansions in chimpanzees and gorillas.







































Next, a 26.9-kbp incomplete segment (SD-A) duplicatively
transposed exons 8, 9, and 10 from CFH to a region immediately
adjacent to the promoter of CFHR4 in the common ape ancestor
(estimated 26 ± 2.0 Mya) (Fig. 3 and SI Appendix, Fig. S10). The
breakpoints of this event map precisely between two direct SD-B
elements (SD-B1 and SD-B2) that contain the promoter and first
exon of CFHR4 (SI Appendix, Fig. S11). Three additional smaller
duplication events likely occurred in the human-chimpanzee-
gorilla ancestor. These included two independent duplications
of the 4.8-kbp CFHR4 promoter (SD-B1 to SD-B3 and SD-B2 to
SD-B4) and a 1.6-kbp duplication (SD-C) from CFH (exons
8 and 9) to the telomeric end of SD-B3 (Fig. 3 and SI Appendix,
Fig. S11). The presence of a complete LINE/L1 element at the
boundary of the SD-C duplication is suggestive of L1-mediated
transduction as previously proposed for the origin of this smaller
duplication (36).
The final series of SDs occurred concurrently or within a very
narrow evolutionary window during the separation of human and
African great ape lineages (5–8 Mya). These included a 40.2-kbp
distal duplication (SD-D) in direct orientation (6.9 ± 0.25 Mya),
creating truncated versions of CFHR4 (exons 7–10) and CFHR2
(exons 1–3). This was followed by a 28.6-kbp duplication (SD-E)
containing C-terminal exons from CFH to the 3′ end of SD-D
(6.6 ± 0.4 Mya). The arrangement of SD-E and SD-D in a “head-
to-tail” configuration, in combination with the juxtaposition of
SD-C and SD-B, established the most recent of the CFHR
paralogs, CFHR3 and CFHR1, which are exclusive to the African
great ape lineage. The last two duplications also create the
genomic architecture necessary for the common/rare deletions
associated with AMD protection. Interestingly, we mapped
the breakpoints of these last duplications to the same 4.8-kbp
CFHR4 promoter segment that defined the breakpoints for one
of the initial duplication events (SD-A) (SI Appendix, Fig. S12).
We note the other SDs that resulted in lineage-specific CFHR
genes also show the SD-B element at the duplication break-
points, including CFHR6 in the chimpanzee and CFH-L3 in the
macaque (SI Appendix, Fig. S11). In total, these data argue
that the promoter duplication SD-B served as a preferential
target for the majority of SDs that led to the emergence of
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Fig. 2. Alternative human structural haplotypes at the 1q31.3 locus. The sequence organization of four common structural haplotypes at 1q31.3 is compared.
Annotations include the location of breakpoints associated with flanking SDs (colored arrows). Regions of CFHR gene gain and gene loss are represented by
colored shading. Large-insert clone tiling paths [BAC (VMRC) and fosmid clone inserts (F designation)] used to assemble each haplotype are shown.



























Gene Innovation, Transcript Diversity, and Selection. We identify
seven distinct CFHR paralogs that arose as a result of duplication
and juxtaposition of nine SDs in the primate lineage (Dataset
S6). Notably, we sequence-resolved 25 gene-intersecting struc-
tural variants >50 bp in size among great apes (Table 1). The
largest predicted ORF results from a 7.6-kbp tandem duplication
of CFHR4 observed in all primates with the exception of humans
and gorillas (Dataset S10). There are some general trends regarding
the evolution of the gene family. First, we have determined that
CFH exons 8 and 9 have been reused at least five times during
the construction of these genes, suggesting that this particular
domain has been a preferential donor of duplicated sequences.
Notably, exon 9 is the same region where the common AMD risk
variant (Y402H) has been mapped (1). Sequence analysis shows
that the H402 variant can be identified among lesser apes, in-
dicating it is at least ∼20 My old and may have arisen at the root
of the ape lineage. Second, we find that SD-B defines the
breakpoints of most primate duplication events, suggesting it has
served as a preferential acceptor. Importantly, this segment
corresponds to the CFHR4 promoter, and we determine that it
has served as a 5′ transcript initiator for at least four CFHR gene
fusions in the primate lineage that maintain an ORF (SI Appendix,
Fig. S11). As an example, a chimpanzee-specific duplication of
CFHR1 resulting from an additional copy of SD-E (SD-E3 estimated
to have occurred 3.7 ± 0.16 Mya) contains this promoter duplication,
defining the telomeric boundary of this event (SI Appendix, Fig. S13).
The juxtaposition of the CFHR4 promoter duplication with two
unique exons from CFHR2 (exons 4 and 5) results in a chimpanzee-
specific 146-aa ORF, which we designate CFHR6. We amplified by
RT-PCR the putative full-length ORF spanning both the pre-
dicted 5′ and 3′ untranslated regions (UTRs) using chimpanzee
RNA generated from liver source material and confirmed ex-
pression of CFHR6 in the chimpanzee liver.
To understand the protein-coding potential and levels of
transcript diversity for this gene family, we focused on the human
organization and mapped isoform sequencing (Iso-Seq) data
generated from liver source material to identify the gene models
based on the most common European CFH structural haplotype
S1. The nearly full-length cDNA data from Iso-Seq allows
paralogs and isoforms to be more readily distinguished. In total,
we identify 12 isoform transcripts (supported by at least one full-
length read and more than one non–full-length read) that were
previously unannotated by the GENCODE or RefSeq database
(Dataset S12). We find no sequence support for seven of 12
GENCODE-predicted isoforms. We find that the most abundant
patterns of alternative splicing occur at CFH, defining four short
CFH CFHR3 CFHR1 CFHR4 CFHR2 CFHR5 F13B
Human
CHM1
CFH CFHR3 CFHR1 CFHR4 CFHR5 F13BCFHR1
Pan troglodytes
CH251
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Pongo abellii
CH276
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Fig. 3. CFHR gene family evolution. Sequence structure and organization of the chromosome 1q31.3 CFHR locus are compared among primates (marmoset,
macaque, orangutan, chimpanzee, and human) based on BAC clone sequencing. Gene models show CFHR gain and loss at different stages with respect to
changes in the SD architecture (colored and shaded arrows represent recent and ancestral SDs, respectively). Sequence alignment and phylogenetic analyses
are used to predict the timing and size of various duplications over 40 My of primate evolution (SI Appendix, SI Materials and Methods).







































and four long isoforms (Fig. 4A). In contrast, CFHR5 is com-
pletely devoid of alternatively spliced transcripts, with all full-
length reads representing the canonical 10-exon, 569-aa ORF.
We identify unannotated exons for three spliced isoforms for
CFH and CFHR2, with the former yielding an increase of
26 amino acids to the ORF of the canonical short CFH isoform
(Fig. 4A). Additionally, we identify an unannotated exon 2 within
the long isoform of CFHR2 that increases the ORF length by
81 amino acids. We also extend the 5′ and 3′ UTRs, and in five
cases, we identify alternative splice donor/acceptor sites (Dataset
S12). To quantitate expression differences between CFHR iso-
forms, we next analyze RNA-sequencing (RNA-seq) data gen-
erated from liver source material (Genotype-Tissue Expression
project) (37) and map these data back to the isoform models. Of
the 25 isoforms used in the analysis, we show that 56% (14 of 25)
are highly expressed in the liver (Fig. 4B), with 67% (eight of 12)
of the unannotated isoforms identified by long-read sequencing
showing the highest expression patterns among CFH and the
gene paralogs (Fig. 4B). While this analysis does not take into
account haplotypic or intrinsic regulatory differences that would
likely impact gene expression levels, it is interesting that four
genes (CFH, CFHR1, CFHR4, and CFHR2) show the highest
expression patterns for the noncanonical isoforms as annotated
by GENCODE. Such data suggest that long-read Iso-Seq will
have a substantial impact in annotating complex/duplication-rich
regions of the genome.
Next, using sequence data generated as part of the 1KG, we
searched for signatures of positive selection, restricting our
analysis to unique regions of 1q31.3. Applying the extended
haplotype homozygosity metric, we found no evidence of recent
selective sweeps for any of the CFH/CFHR loci (CFH, CFHR5,
and F13B) in the human population (SI Appendix, Figs. S14 and
S15). Finally, using a high-quality sequence generated from both
primate and multiple human haplotypes, we also investigated the
ratio of nonsynonymous to synonymous variation (omega = ω) as
a measure of selective pressure on CFH and its gene paralogs.
We incorporated data generated from SMRT sequencing of
large-insert clones (14 sequenced haplotypes and 21 fosmid in-
serts) and phased whole-genome sequencing short-read Illumina
data from the HGDP (76 haplotypes) (Dataset S13). Only at the
ancestral CFH locus did we observe an elevated nonsynonymous
change (dN)/synonymous change (dS) value consistent with sig-
nals of positive selection (P = 1.14 × 10−17, dN/dS ω = 7.6)
(280.66 kbp of coding sequence). At the protein level, we esti-
mate that ∼3.5% of amino acid sites show signatures of positive
selection and identify 12 unique amino acid sites that remain
significant after correction (P < 0.05) (Fig. 4C and Dataset S13).
Notably, these sites intersect sites of SD (seven of 12 of the
positively selected amino acid sites) or functional binding do-
mains such as C3b (seven of 12 domains) or glycosaminoglycan
domains (five of 12 domains) (Fig. 4D). For example, we
identify a cluster of three positively selected amino acids
(1,200, 1,203, and 1,213) located in short consensus repeat
(SCR) domain 20, a domain important for discriminating
between self- and non–self-complement activation.
Disease Association. We designed 405 molecular inversion probe
(MIP) assays to distinguish and sequence CFH and CHFR
paralogs (including F13B) in humans, taking advantage of singly
unique nucleotide identifiers that distinguish paralogous copies
(Dataset S14). We sequenced the coding portion of these genes
in 1,574 AMD cases and 855 controls from three separate co-
horts. Analysis of these cohorts replicated previous findings that
showed an excess of common, private, and damaging missense
mutations of the ancestral CFH in association with AMD (38)
(Datasets S15–S17). Interestingly, we also found four significant
AMD associations with coding mutations in CFHR paralogs,
including a rare putative loss-of-function mutation [P = 0.003,
odds ratio (OR) = 3.6, 95% confidence interval (CI) (1.7–9.8)
adjusted for age and gender] and a severe missense mutation
[P = 6.88 × 10−6, OR = 0.26, 0.95 CI (0.14–0.40) adjusted for age
Table 1. Gene-intersecting structural variation (>50 bp) detected among humans and NHPs
Gene GRCh37 coordinates Primates Size, bp SV type
CFH Chr1:196699022–196700021 Orangutan 999 Deletion
CFH Chr1:196681710–196682216 Orangutan 506 Deletion
CFH Chr1:196628274–196628275 Chimpanzee, gorilla, orangutan 50 Insertion
CFH Chr1:196714624–196714625 Chimpanzee 56 Insertion
CFH Chr1:196652722–196652723 Gorilla 323 Insertion
CFH Chr1:196706208–196706209 Orangutan 304 Insertion
CFH Chr1:196662187–196662188 Orangutan 5,586 Insertion
CFH Chr1:196636697–196636698 Orangutan 6,132 Insertion
CFHR3 Chr1:196761302–196761358 Chimpanzee, gorilla 327 Deletion
CFHR3 Chr1:196758756–196758764 Chimpanzee, gorilla 369 Insertion
CFHR3* Chr1:196734114–196748223 Human ∼14,110 Deletion
CFHR1 Chr1:196920353–196920890 Chimpanzee 26,596 Duplication
CFHR3, CFHR1 Chr1:196726714–196811885 Human 84,683 Deletion
CFHR1, CFHR4 Chr1:196782714–196904670 Human 121,898 Deletion
CFHR1, CFHR4 Chr1:196787137–196912332 Human 124,017 Deletion
CFHR1, CFHR4† Chr1:196763623–196763901 Human 125,164 Deletion
CFHR4 Chr1:196872498–196872844 Orangutan 346 Deletion
CFHR4 Chr1:196872237–196872238 Orangutan 79 Insertion
CFHR4 Chr1:196878738–196878739 Orangutan 177 Insertion
CFHR4 Chr1:196880789–196880844 Chimpanzee 7,630 Insertion
CFHR4 Chr1:196880789–196880844 Orangutan 15,584 Insertion
CFHR2 Chr1:196920020–196920095 Gorilla 75 Deletion
CFHR5 Chr1:196976072–196976443 Gorilla 371 Deletion
CFHR5 chr1:196961355–196961491 Orangutan 136 Deletion
CFHR5 chr1:196977326–196977327 Orangutan 208 Insertion
SV, structural variant.
*Unable to estimate breakpoints by MIP resequencing.
†Breakpoint size estimated by MIP resequencing.



























and gender] [combined annotation-dependent depletion (CADD)
score = 23] in CFHR2 (Datasets S18 and S19).
To create a more refined map of potential pathogenic mutations
in the ancestral CFH, we combined our data with variant calls from
five resequencing studies (38–41), which were limited to the CFH
locus. In the combined set, we identify a total of 101 CFH missense
mutations in >5,000 individuals (3,452 cases and 1,645 controls).
Among this nonredundant set of missense mutations, 48.5% (49 of
101) have not been observed in Exome Aggregation Consortium
(ExAC), with a further 42.6% (43 of 101) of mutations demon-
strating a CADD score of >20 (Dataset S20). Likely gene-disruptive
(LGD) mutations were identified solely in AMD cases at a fre-
quency of 0.28% versus 0% in controls [P = 0.01987, OR =
(1.37-Inf), Fisher’s exact test where Inf = Infinity]. Similarly, we
identify 37 private (absent from ExAC) deleterious missense
mutations (CADD score > 20) in AMD cases and one mutation
in controls [1.07% vs. 0.06%; P = 6.29 × 10−6, OR = 17.9 (3.58-Inf),
Fisher’s exact test]. This association became stronger when
we restrict on frequency (<0.001), identifying 61 in AMD cases
and three in controls [P = 5.81 × 10−8, OR = 9.8 (3.67-Inf),
Fisher’s exact test] (Fig. 5A and Dataset S16). Notably, we identify
four amino acids that have increased burden (more than four
mutations) in AMD cases, with no occurrences identified in
controls (R53C, R127P/H, D130N, and P562H). These are likely
candidates for high-impact mutations among AMD patients; how-
ever, they did not reach statistical significance.
Previous studies have observed a nonrandom pattern of
pathogenic mutations with respect to CFH protein domains (38,
42), namely, N terminus for patients with AMD and C terminus
for patients with AHUS. Among the private deleterious missense
mutations, we find that 59% (23 of 39) map to SCR domains 1–5
(Fig. 5A). Similarly, an analysis of 106 private missense muta-
tions identified in the AHUS factor H database (43) shows that
43% (46 of 106) of mutations are located within SCR domains
19 and 20 (Fig. 5B). To assess the significance of these observa-
tions, we apply an unbiased clustering approach using CLUstering
by Mutation Position (CLUMP) (44) to first compare the pat-
tern of missense variation in AMD cases versus controls and
then separately compared with a population control of 503
European individuals from the 1KG. In both cases, we identify
significant clustering around medoids (CLUMP score = 1.19;
P < 10−3) for AMD-associated missense mutations (Fig. 5A). As
AHUS mutations are typically more deleterious than those described
in AMD, we compare our list of mutations with 182 private missense
alleles detected in ExAC. Once again, we observe significant clus-
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common marmoset I H D S K Q L M R V S S
green monkey I N S S M R W M V V S P
crab ea ng macaque I D H N T R R T V K S P
rhesus macaque I D P P T R R T V K S P
gibbon I N S S R H H T V V P T
orangutan I D H H M Q H T V V Y P
gorilla I D H H T W H I V V H T
chimpanzee I N R R T W H A V I N A
human (NA18517) I D H H T W H T V V R T
human (CHM1) V D H H T W H T V V R T
human (NA19129) I D H H T W H T V V R T
human (NA18956) I D H Y T W H T V V R T
human (NA19449 hapA) I D H H T W H T V V R T
human (NA19449 hapB) V D H Y T W H T V V R T
human (NA19434) I D H Y T W H T V V R T
human (NA19240) I D H H T W H T V V R T
human (HG0733) I D H Y T W H T V V R T







RNA-seq expression of CFH and CFHR isoformsCFH and CFHR2 isoforms
splice acceptor
Fig. 4. Gene family selection and expression. (A) Iso-Seq identifies two main canonical isoforms of CFH: a long isoform (22 exons) and a short isoform
(10 exons) (annotated in black), with unannotated isoforms depicting alternatively spliced exons and their coding potential. Similarly, Iso-Seq identifies
two major CFHR2 transcripts, including unannotated isoforms containing alternatively spliced exons 2 and 3 (annotated in red) and an unannotated exon
2 (annotated in orange). (B) RNA-seq reads from liver source tissue [GTEx Consortium (37)] were used to estimate expression [transcripts per million (TPM)]
of full-length PacBio-sequenced isoforms from CFH and its duplicate gene paralogs. CFH demonstrates the highest expression level in the liver; however,
three of the youngest CFH gene paralogs (CFHR1, CFHR3, and CFHR2) are highly expressed relative to evolutionary older gene paralogs (CFHR5 and
CFHR4). Box plots indicate median and interquartile range (IQRs) with outliers shown beyond 1.5 × IQR. (C ) Twelve sites of positive selection (P < 0.05) are
shown for CFH based on the ratio of nonsynonymous to synonymous changes (dN/dS) for the canonical ORF (1,231 amino acids). (D) Sites of positive
selection are projected onto the CFH protein model with short consensus repeat domains annotated in blue, SDs annotated in gray, and binding domains
annotated in green and orange.







































to the opposite end of the protein (Fig. 5B). Interestingly, we find
that ∼53% (56 of 106) of private AHUS mutations and 28.6%
(16 of 56) of AMD mutations map to SCR domains where we also
report evidence of positive selection at the amino acid level, in-
cluding the two missense mutations (Y402H and V62I), which tag
as the reported risk (H1) and protective (H2) haplotypes in AMD.
Using a random distribution of AMD and AHUS mutations across
the CFH protein, we tested by simulation (10,000 permutations)
whether AMD and AHUS variants were significantly more likely to
fall in protein domains under selection. Notably, we find that
AHUS variants are significantly enriched in these domains (P =
0.002); however, this did not reach statistical significance for AMD
under this model (P = 0.084).
Recurrent CNVs, Mutational Burden, and Disease Risk. CNVs of the
CFHR gene cluster have been associated with three immune
diseases (AHUS, SLE, and AMD); however, the breakpoints of
these events, with a few exceptions (22), have not typically been
resolved in patients beyond those afforded by microarrays. We
took advantage of our diversity panel of sequence-resolved
haplotypes coupled to the targeted resequencing of duplicate
loci to identify and refine both rare and common CNVs in 2,427
AMD cases and controls. Since our sequencing assays focused on
sequence differences among the duplicated CFHR genes, the
assays allowed us to distinguish canonical from alternate break-
point signatures mapping within the mediating SDs (SD-D and
SD-E) (SI Appendix, Fig. S17). In total, we identify eight struc-
turally distinct haplotypes with variable frequency in this cohort
(Fig. 5C and Datasets S7 and S21), seven of which correspond to
deletions and duplications of CFHR3, CFHR1, and CFHR4. Fo-
cusing on the structural variants thought to be protective against
AMD, we identify five distinct NAHR-mediated structural variants:
three corresponding to the CFHR1–CFHR4 and two corresponding
to the CFHR1–CFHR3. We designate the nonreciprocal CFHR1–
CFHR4 structural variant haplotype as S8 (breakpoints estimated to
map ∼700 bp upstream of the 3′ UTR of CFHR4) and the non-
reciprocal CFHR3 deletion haplotype as S7 (Fig. 5C). Due to the
lack of informative PSVs that distinguish the S3 and S4 CFHR1–
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Fig. 5. Recurrent and clustered mutations associ-
ated with disease. (A) Pattern of missense variation
in >5,000 AMD cases (purple; n = 3,452) versus con-
trols (black; n = 1,645) is plotted against a schematic
of the CFH protein with SCR domains (blue). Missense
mutations in cases are significantly clustered (tan
highlighted region) around SCR domains 1–5 as de-
termined by CLUMP analysis. (B) Pattern of missense,
splice-site, and indel variation (152 total mutations) in
AHUS cases (www.fh-hus.org/fullList.php?protein=FH)
is similarly plotted. AHUS missense mutations signifi-
cantly cluster around SCR domains 18–20 (highlighted).
(C) Refinement of five NAHR-mediated breakpoints
(colored vertical boxes) with respect to SD (colored
horizontal arrows) and CFHR gene family organization
indicates recurrent rearrangements. The size and per-
cent sequence identity of the SDs that mediate the
rearrangements are shown.



























two haplotypes with certainty using our MIP genotyping assay (SI
Appendix, Fig. S3 B and C).
Consistent with previous reports that deletions are protective
(21, 22, 45, 46), we observe that control individuals are enriched
for haplotypes carrying the deletion of CFHR3-1 [P = 2.2 × 10−16,
OR = 0.35, 0.95 CI (0.30–0.41)] or CFHR1-4 [P = 0.01, OR =
0.43, 0.95 CI (0.22–0.83) adjusted for age and gender]. While we
could not stratify all CFHR1-4 structural variants by haplotype
(36 deletion and 4 duplication carriers), it is interesting that only
the S4 duplication haplotype breakpoint maps within 565 bp of
the 5′ UTR of CFHR2, while the other two deletion haplotypes
(S3 and S8) have their breakpoints at least 5,000 bp away from
this gene. This suggests that expression of CFHR2 may also be
disrupted if a reciprocal deletion occurs on this haplotype.
Similarly, for CFHR1–CFHR3 deletions, we find the protective
association only with haplotype S2 but note that S7 could only
be confidently assigned in one individual (and we are thus
underpowered to assess its effect on AMD disease risk). The
latter structural haplotype is interesting because the break-
points map precisely to the SD-B “promoter” duplication,
which was critical to the evolution of the gene cluster.
Discussion
Here, we performed targeted long-read sequencing of the CFH
family in multiple humans and NHPs in an effort to understand the
evolution, genetic diversity, and transcript potential of this locus as
it relates to complex diseases, such as AMD and AHUS. Because
recent SDs are enriched for misassembly, the high-quality se-
quence resource (10.6 Mbp) closes an estimated 93 gaps in
primate genomes, discovers new paralogous genes, and signifi-
cantly improves gene and genome annotation. Our evolutionary
reconstruction and disease analysis highlight several important
features.
First, incomplete gene duplication has been the predominant
mechanism for evolutionary change at the CFHR locus. Specif-
ically, we find no evidence of a complete duplication of the CFH
locus; rather, the most common human genome organization
arose as a result of at least 12 incomplete SDs, where each du-
plication event harbored a few protein-coding exons. This
mechanism has the potential for rapid neofunctionalization (as
well as pseudogenization) because the new duplicate genes at the
time of their inception lack a complete ORF but differ radically
in structure from the progenitor loci (47). Recent functional data
for several human CFHR proteins support this observation (28,
29, 48, 49). For example, a recent study reported that CFHR3
functions as an inhibitor protein capable of blocking C3d-
mediated B cell activation (48). The juxtaposition of three in-
complete SDs at this position effectively rescued these partial
gene duplications from pseudogenization, and CFHR3 thus ac-
quired novel B cell regulatory function.
Second, the process of duplication appears highly nonrandom
in that we observe preferential donor and acceptor sequences
for all duplicative transpositions. Specifically, during primate
evolution, an SD cassette corresponding to CFH exons 8 and
9 was duplicated at least five times, leading to the evolution of
three of the CFHR family members. Similarly, we identify reuse
of the CFHR gene promoter duplication (SD-B) as a prefer-
ential acceptor region. Our phylogenetic analysis shows that
this ∼4.8-kbp sequence expanded on at least four occasions
independently (copy number ranging from four to 12 copies),
preceding and defining the breakpoints of larger evolutionary
duplications in most primate lineages. For example, SD-B copy
number expansion in ancestral African apes occurred before
and defines the boundaries of the >85-kbp duplicative trans-
position that predisposes to common rearrangements associ-
ated with immune disease (6, 22, 23). Remarkably, this same
sequence acts as a 5′ transcript initiator for at least four CFHR
fusion genes, including a lineage-specific CFHR gene, CFHR6,
in chimpanzees. The results suggest a particularly prolific and
unstable genomic element driving transcription akin to the “core”
duplicons that demarcate the boundaries of African ape SD ex-
pansion genome-wide (50, 51). While the evolutionary origin of
the promoter duplication is uncertain, it is noteworthy that the
5′ UTR and exon of this cassette are conserved in the mouse,
where they are associated with two rodent-specific CFHR fu-
sion genes. In conjunction with CFH exons 8 and 9 donor du-
plications, this suggests broader reuse of this element during
mammalian evolution.
Third, rare missense/LGD mutations associated with disease
are nonrandomly distributed and cluster in distinct protein
domains of CFH (N terminus for AMD and C terminus for
AHUS). Consistent with previous observations, low-frequency
deleterious mutations (CADD score > 20) are enriched among
AMD cases and exhibit a distinct N-terminal clustering pattern
(38). We observe a fivefold enrichment of LGD mutation and a
tenfold enrichment of rare mutation (<0.001 frequency based
on ExAC). This effect becomes stronger when restricting to
private mutations [P = 6.29 × 10−6, OR = 17.9 (3.58-Inf)]
(Dataset S16). Putative pathogenic missense/LGD mutations
frequently map to canonically spliced exons (SI Appendix, Fig.
S18), despite CFH exhibiting complex patterns of alternative
splicing (Dataset S12). Importantly, missense and LGD muta-
tions cluster in protein domains that also show signals of se-
lection. In some cases, positive selection occurs at sites that are
themselves susceptibility alleles for AMD and AHUS (V62,
Y402, R1203, and V1200) (1, 52, 53). These protein domains
are also binding sites for several pathogenic microbes (54–56),
suggesting that natural selection has shaped a portion of the
genetic variation at CFH underlying susceptibility to immune-
associated diseases.
Finally, we provide evidence of recurrent and nonreciprocal
deletions and duplications of the cluster. While previous stud-
ies have shown that both deletions CFHR3/1 (21, 22) and
CFHR1/4 (45) are protective in AMD, our copy number anal-
ysis shows that these rearrangements occur as a result of five
distinct classes of breakpoints with variable frequency in this
cohort (Fig. 5C and Dataset S21). The S4 breakpoint, for example,
occurs in close proximity to the promoter of CFHR2 and may also
result in disruption of its expression. Notably, we identify a
structural haplotype (S7) that likely removes the promoter and
first exon of CFHR3. While this haplotype appears to be rare, it is
interesting that the deletion is mediated by the same duplications
(SD-B) critical in restructuring the locus throughout primate evo-
lution. In total, these observations suggest that fine-scale mapping
of CNV deletion breakpoints in combination with enhanced variant
detection (particularly among duplicate gene paralogs) will be in-
creasingly important for discriminating disease and at-risk haplo-
types more broadly for this locus.
Materials and Methods
Detailed methods, including copy number genotyping, PacBio sequence and
assembly, phylogenetic and evolutionary analysis, PacBio Iso-Seq, RNA-seq
expression analysis, patient data, and Illumina-based short-read sequenc-
ing, are provided in SI Appendix. All groups collected data according to
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